Are you looking for a treatment method for your child that can specifically kill tumor cells without significant toxic side effects? Sun Yat-Sen Memorial Hospital Biotherapy Center and Pediatric Hematology Oncology Specialists of Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University can now jointly provide a new bioimmunotherapy technology for pediatric hematology tumors, which is specifically designed to solve the above problem for you. 1. What is autologous cytokine-induced killer (CIK) cells? CIK cells are a heterogeneous group of cells obtained from the child’s own peripheral blood mononuclear cells after stimulation with various cytokines in vitro, which have cytotoxic activity of killing T cells and NK cells. With the characteristics of rapid proliferation, high tumor-killing activity, broad tumor-killing spectrum, and slight effect on normal hematopoiesis, they have high application value in the clinical treatment of tumor, hematological system diseases and some infectious diseases. 2.Tumor killing mechanism of autologous CIK cells? (1) Natural killing effect: CIK is a non-MHC-restricted cytotoxic cell that acts as a lysis agent for tumor cells. (2) Inflammatory cytokine effect: CIK activation produces a large number of inflammatory cytokines with tumor suppressive and tumor killing activity. (3) CIK induces apoptosis of tumor cells. (4) Tumor-killing effect by enhancing T-cell function. (5) It is also sensitive to multi-drug resistant tumor cells. 3. Indications for autologous CIK cell infusion (1) Maintenance therapy after chemotherapy for childhood lymphoma or other malignant solid tumors (stage III or above). (2) Maintenance therapy after chemotherapy for childhood myeloid leukemia (acute non-gonorrhea). (3) Palliative adjuvant treatment for children with refractory malignant tumors (not invading bone marrow) in the interval of chemotherapy. 4.What are the advantages of autologous CIK cell infusion over general conventional chemotherapy? In vivo transfusion of immune autologous CIK cells can kill tumor cells directly without damaging the structure and function of the body’s immune system, and also have a killing effect on chemotherapy-resistant tumor cell lines, without affecting the formation of normal hematopoietic cell colonies; it can also regulate and enhance the body’s immune function, kill small residual lesions, resist immune escape, and reduce the recurrence rate; after infusion, it can not After infusion, autologous CIK cell infusion-related graft-versus-host disease can not occur, and can continue to mediate the anti-tumor killing effect, thus becoming an important adjuvant anti-tumor method for pediatric hematologic tumors in addition to surgery, radiotherapy, chemotherapy and other treatments. 5.How to do the biological therapy of autologous CIK cell infusion? We need to collect 30-50ml of autologous peripheral venous blood from the child and add various cytokines to induce CIK cell expansion, which takes 14-21 days to complete. Every 4-8 weeks, the child receives an autologous CIK cell infusion. 6.Is there any toxic effect of autologous CIK cell infusion? However, since autologous CIK cells can continue to secrete a variety of cytokines with anti-tumor effects after infusion, chills and fever may occur during the treatment process, and a few patients may have fatigue, muscle aches and other flu-like symptoms, which can disappear quickly after symptomatic treatment, without other obvious toxic side effects. CIK cell infusion charge: RMB12000/time (medical insurance program).